



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 142 996 A8**

(12)

CORRECTED EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)
INID code(s) 71

(51) Int Cl.7: **C12N 15/08**, C07K 16/18,
C12N 5/12, C12P 21/08,
G01N 33/53, G01N 33/577

(48) Corrigendum issued on:

30.01.2002 Bulletin 2002/05

(86) International application number:
PCT/JP99/07106

(43) Date of publication:

10.10.2001 Bulletin 2001/41

(87) International publication number:
WO 00/37632 (29.06.2000 Gazette 2000/26)

(21) Application number: **99959883.2**

(22) Date of filing: **17.12.1999**

(84) Designated Contracting States:

DE FR GB

(30) Priority: **22.12.1998 JP 36429598**

(71) Applicant: **DAIICHI PURE CHEMICALS CO. LTD.**
Chuo-ku Tokyo 103-0027 (JP)

(72) Inventors:

- **MIYAZAKI, Osamu**
Daiichi Pure Chemicals Co., Ltd.
Naka-gun, Ibaraki 319-1112 (JP)

- **FUKAMACHI, Isamu**
Daiichi Pure Chemicals Co., Ltd.
Naka-gun, Ibaraki 319-1112 (JP)

(74) Representative: **Hartz, Nikolai F., Dr. et al**
Wächtershäuser & Hartz, Patentanwälte, Tal 29
80331 München (DE)

(54) **MONOCLONAL ANTIBODY AGAINST APOLIPOPROTEIN A-I**

(57) The present invention is drawn to a monoclonal antibody reacting specifically with (1) apoA-I occurring in HDL containing no apoA-II and having a molecular weight of 150,000 or less; and (2) apoA-I not binding to a lipid; a hybridoma producing this antibody; a method

of immunologically assaying apoA-I characterized by reacting the antibody with a specimen; and an assay reagent for apoA-I which contains the antibody. The invention realizes measurement of a specific apoA-I, which provides a novel index of lipid metabolism disorder, etc.

EP 1 142 996 A8